AGN-2979

AGN-2979 is an experimental drug that was developed by Allergan for the treatment of depression. It acts as a selective inhibitor of tryptophan hydroxylase, which is a rate-limiting enzyme in the biosynthesis of serotonin. This mechanism of action is unique among antidepressants.

Mechanism of action

AGN-2979 inhibits tryptophan hydroxylase, a rate-limiting enzyme in the biosynthesis of serotonin. This results in decreased levels of serotonin, which is a neurotransmitter that plays a key role in mood regulation. By inhibiting the production of serotonin, AGN-2979 may help to alleviate symptoms of depression.

Development and clinical trials

Allergan, a global pharmaceutical company, developed AGN-2979. The drug underwent clinical trials to evaluate its safety and efficacy in treating depression. However, the results of these trials have not been publicly disclosed, and it is unclear whether Allergan plans to continue developing the drug.

See also

• Antidepressant
• Serotonin
• Tryptophan hydroxylase
• Allergan

References

AGN-2979 Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.

Translate to: East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski